Latest News for: 2359

Edit

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily ...

Nasdaq Globe Newswire 16 Dec 2025
In mCRPC patients with androgen receptor (AR) ...
Edit

MRT-2359 Phase 1/2 Clinical Data Update (Monte Rosa Therapeutics Inc)

Public Technologies 16 Dec 2025
MRT-2359 Phase 1/2 Clinical Data Update ... Combination of MRT-2359 and enzalutamide was well tolerated with mild or moderate manageable GI adverse events ... MRT-2359 Exploits Key Therapeutic Vulnerabilities in Therapy-Resistant CRPC ... MRT-2359.
Edit

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations (Form 8-K) (Monte Rosa Therapeutics Inc)

Public Technologies 16 Dec 2025
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations ... About MRT-2359.
Edit

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Nasdaq Globe Newswire 15 Dec 2025
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results ... .
  • 1

Article Search

tools
×
×
×
×